Tresiba Explained: How It Works and Who It's For

Tresiba at a glance:

• Drug class: Ultra-long-acting basal insulin analog
• Manufacturer: Novo Nordisk
• FDA approved: 2015
• Route: subcutaneous injection (FlexTouch pen)
• Typical frequency: once daily; flexible timing
• Half-life: ~25 hours (duration of action >42 hours)
• Cash price (US): ~$420–$480/month list; $35/month cap for Medicare beneficiaries

If you're trying to figure out whether Tresiba is right for you — or for someone you care about — the right starting point is the basic biology. Tresiba is a ultra-long-acting basal insulin analog made by Novo Nordisk and approved by the FDA in 2015. Comparable A1c reduction to glargine with significantly lower rates of nocturnal hypoglycemia (DEVOTE).

What is Tresiba?

Insulin degludec forms soluble multi-hexamers in subcutaneous tissue that release slowly into circulation, producing a flat duration of action exceeding 42 hours.

Tresiba is manufactured by Novo Nordisk. Tresiba was approved by the FDA in 2015. Its approved indications include type 1 diabetes, type 2 diabetes. Off-label use happens in clinical practice but is the prescriber's responsibility.

The drug class ultra-long-acting basal insulin analog works by targeting specific receptor pathways. Let's walk through what that means in practice.

How Tresiba Works in the Body

Insulin degludec forms soluble multi-hexamers in subcutaneous tissue that release slowly into circulation, producing a flat duration of action exceeding 42 hours. The receptor target — compound-specific — drives the downstream effects users care about: comparable a1c reduction to glargine with significantly lower rates of nocturnal hypoglycemia (devote).

The pharmacokinetics matter for daily use. Tresiba has a half-life of ~25 hours (duration of action >42 hours), which determines how often it is dosed. The standard route of administration is subcutaneous injection (FlexTouch pen), and the typical schedule is once daily; flexible timing.

For more detail on the underlying biology, see our breakdown of how Tresiba works.

Who Uses Tresiba?

Tresiba is most relevant for people whose situation maps to its approved indications: type 1 diabetes; type 2 diabetes.

People who should avoid Tresiba include those with the following:

• hypoglycemia

Common and Serious Side Effects

The most commonly reported side effects of Tresiba include:

• hypoglycemia
• weight gain
• injection-site reactions

Serious risks — uncommon but worth knowing — include:

• severe hypoglycemia

We have a more detailed breakdown in our Tresiba side-effects guide.

Tresiba vs Alternatives

Lantus (glargine), Levemir (detemir), and Toujeo are alternative basal insulins. If you are weighing Tresiba against another option, our comparison pages include Tresiba Side Effects in 2026: Real Reports, Real Solutions, Real Tresiba Results: What 6 and 12 Months Actually Look Like, Tresiba Cost in 2026: What You'll Actually Pay (Real Numbers).

Bottom Line

Tresiba delivers what its label says it delivers. The case for it (or against it) comes down to your specific situation, not abstract comparisons. Multiple randomized controlled trials support its efficacy. If you are considering Tresiba, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Related Reading

• Tresiba Side Effects in 2026: Real Reports, Real Solutions
• Real Tresiba Results: What 6 and 12 Months Actually Look Like
• Tresiba Cost in 2026: What You'll Actually Pay (Real Numbers)
• Tresiba Protocols: A Research-Based Overview (Not a Recommendation)
• Is Lantus Right for You? An Evidence-Based Breakdown
• What Is Humalog? Everything You Should Know Before Starting

Sources

• American Diabetes Association. Standards of Care in Diabetes — 2024. Diabetes Care 2024;47(Suppl 1).
• Heise T et al. Insulin Pharmacokinetics and Pharmacodynamics. Diabetes Obes Metab 2017;19:3.

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.